DOCSLIB.ORG

Listening, Responding and Working Toward a Healthier Future

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Listening, Responding and Working Toward a Healthier Future Listening, responding and working toward a healthier future OUR COMMITMENT, PERFORMANCE, IMPACT AND ASPIRATIONS Corporate Responsibility 2006–2007 Report FOLD HINGE SPINE HINGE Our Medicines and Vaccines PRODUCT NAME THERAPEUTIC AREA ATHEROSCLEROSIS & CARDIOVASCULAR Cozaar® (losartan potassium) High blood pressure Hyzaar® (losartan potassium and hydrochlorothiazide) High blood pressure Sustainable business success depends on making quality products that Vytorin® (ezetimibe/simvastatin)* High cholesterol Zetia® (ezetimibe)* High cholesterol DIABETES & OBESITY people value, on sound fi nancial stewardship and on responsible governance Janumet® (sitagliptin/metformin HCI) Type 2 diabetes Januvia® (sitagliptin phosphate) Type 2 diabetes INFECTIOUS DISEASES that ensures we meet customers’ needs ethically and transparently. Atripla® (efavirenz 600mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)† HIV infection Cancidas® (caspofungin acetate) Certain fungal infections Ut wisi enim ad minim veniam, quis Duis autem vel eum iriure dolor in Duis autem vel eum iriure dolor in Ut wisi enim ad minim veniam, quis Duis autem vel eum iriure dolor in Duis autem vel eum iriure dolor in consequat,Crixivan vel® (indinavir illum sulfate) dolore eu feugiat ullamcorper suscipit lobortis nisl utHIV infectionullamcorper suscipit lobortis nisl ut nostrud exerci tation hendrerit in vulputate velit esse molestie hendrerit in vulputate velit esse molestie nostrud exerci tation hendrerit in vulputate velit esse molestie hendrerit in vulputate velit esse molestie nulla Invanzfacilisis.® (ertapenem sodium) aliquip ex ea commodo consequat.Certain bacterialaliquip infections ex ea commodo consequat. consequat, vel illum dolore eu feugiat consequat, vel illum dolore eu feugiat consequat, vel illum dolore eu feugiat consequat, vel illum dolore eu feugiat Isentress® (raltegravir) HIV infection Duis autem vel eum iriure dolor in nulla facilisis. nulla facilisis. Duis autem vel eum iriure dolorrelations in and nullareturning facilisis. value to share- we have focusednulla our facilisis. CR reporting on volutpat. Ut wisi enim ad minim Duis autem vel eum iriure dolor in Duis autem vel eum iriure dolor in George W. Merck, our founder’s son, believed that placing ® hendrerit in vulputate velit esse molestie ABOUT MERCKhendrerit in vulputate velit esseholders. molestie We seek to maintain high ethi- critical, nonfi nancial material issues. We veniam,Primaxin quis (imipenemnostrud andexerci cilastatin) tation hendrerit in vulputate velit esse molestieCertain bacterialhendrerit infections in vulputate velit esse molestie cal standards and a culture that values provide greater detail than we have in the consequat,patients vel illum dolore before eu feugiat profiLorem ts ipsum was dolor sitboth amet, consect- good medicineLorem ipsum dolor sitand amet, consect- good consequat, vel illum dolore eu feugiat Lorem ipsum dolor sit amet, consect- Lorem ipsum dolor sit amet, consect- Duis Stocrinautem® (efavirenz)vel eum‡ iriure dolor in consequat, vel illum dolore eu feugiatHIV infection consequat, vel illum dolore eu feugiat nulla facilisis. etuer adipiscing elit, sed diam nonummy etuer adipiscing elit, sed diam nonummy Merck & Co.,nulla Inc. facilisis.(Whitehouse Station, honesty, integrityetuer andadipiscing transparency elit, sed in diam nonummypast on these issues,etuer adipiscing especially inelit, terms sed ofdiam nonummy hendrerit in vulputate velit esse molestie nulla facilisis. nulla facilisis. NEUROSCIENCE & OPHTHALMOLOGY nibh euismod tincidunt ut laoreet nibh euismod tincidunt ut laoreet NJ, USA) is a global research-driven all that we do.nibh Company euismod decisions tincidunt are ut laoreetour challenges,nibh metrics euismod and targets.tincidunt ut laoreet consequat, vel illum dolore eu feugiat business. His values live on in Merck today through our 1 ® (dorzolamide hydrochloride and timolol maleate) Elevated intraocular pressure Lorem ipsum dolor sit amet, consect- dolore magna aliquam erat volutpat. Ut dolore magna aliquam erat volutpat. Ut pharmaceuticalLorem company ipsum that dolor discovers, sit amet, consect-driven by whatdolore is right magna for patients. aliquam erat volutpat. Ut dolore magna aliquam erat volutpat. Ut nulla Cosoptfacilisis. Lorem ipsum dolor sit amet, consect- Lorem ipsum dolor sit amet, consect- We have used several external guidelines ® etuer adipiscing elit, sed diam nonummy wisi enim ad minim veniam, quis nos- wisi enim ad minim veniam, quis nos- develops, manufacturesetuer adipiscing and markets elit, sed a diam nonummy wisi enim ad minim veniam, quis nos- wisi enim ad minim veniam, quis nos- Maxalt (rizatriptan benzoate) etuer adipiscing elit, sed diam nonummyAcute migraine etuer adipiscing elit, sed diam nonummy commitment to innovative drug research and discovery, broad range of innovative vaccines and and measurement frameworks to inform nibh euismod tincidunt ut laoreet trud exerci tation ullamcorper suscipit trud exerci tation ullamcorper suscipit nibh euismod tincidunt ut laoreet trud exerci tation ullamcorper suscipit trud exerci tation ullamcorper suscipit LoremTimoptic-XE ipsum dolor® (timolol sit maleate amet, ophthalmic consect- gel formingnibh solution) euismod tincidunt ut laoreet Elevated intraocularnibh euismod pressure tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut lobortis nisl ut aliquip ex ea commodo lobortis nisl ut aliquip ex ea commodo medicines to doloreaddress magna unmet aliquam medical erat volutpat. Ut lobortis nisl ut aliquip ex ea commodothe scope of ourlobortis reporting. nisl utThese aliquip include ex ea commodo etuer adipiscing elit, sed diam nonummy dolore magna aliquam erat volutpat. Ut dolore magna aliquam erat volutpat. Ut ethical business practices, and working to ensure access Trusopt® (dorzolamide hydrochloride) Elevated intraocular pressure wisi enim ad minim veniam, quis nos- consequat. consequat. needs. Merckwisi operates enim as ad Merck minim Sharp veniam, & quisABOUT nos- THISconsequat. REPORT the Global Reportingconsequat. Initiative (GRI 3) nibh euismod tincidunt ut laoreet wisi enim ad minim veniam, quis nos- wisi enim ad minim veniam, quis nos- Guidelines,3 the Millennium Development trud exerci tation ullamcorper suscipit Dohme (MSD)trud in exercimost countries tation ullamcorper outside suscipit doloreONCOLOGY magna aliquam erat volutpat. Ut trud exerci tation ullamcorper suscipit trud exerci tation ullamcorper suscipit to medicines and vaccines for those who need them. This report covers Merck’s CR perfor- Goals4 and the Access to Medicines Index.5 lobortis nisl ut aliquip ex ea commodo Duis autem vel eum iriure dolor in Duis autem vel eum iriure dolor in the United States.lobortis Because nisl ut of aliquip what weex ea commodo Duis autem vel eum iriure dolor in Duis autem vel eum iriure dolor in wisi enimEmend ad® (aprepitant) minim veniam, quis nos- lobortis nisl ut aliquip ex ea commodoPrevention oflobortis postoperative nisl or ut chemotherapy-induced aliquip ex ea commodo nausea and vomiting consequat. hendrerit in vulputate velit esse molestie hendrerit in vulputate velit esse molestie do, we recognizeconsequat. that we have special mance duringhendrerit 2006–2007, in vulputate with some velit esseWe molestie are pleased hendrerit to have achieved in vulputate a reporting velit esse molestie trud exerci tation ullamcorper suscipit consequat. consequat. ® Globalization and the expandingconsequat, reach vel illum of fi dolore rms euduring feugiat the consequat,past decades vel illum have dolore escalatedeu feugiat obligations to society. Accordingly, the additional informationconsequat, relating vel illum to dolore 2008, eu feugiatlevel of B on theconsequat, GRI 3 Guidelines, vel illum dolore eu feugiat lobortisEmend nisl for ut Injection aliquip (fosaprepitant ex ea commodo dimeglumine) Intravenous prevention of chemotherapy-induced nausea and vomiting Duis autem vel eum iriure dolor in nulla facilisis at vero eros et accumsan et nulla facilisis at vero eros et accumsan et stated missionDuis of Merck autem is vel to eumprovide iriure dolorand in updates thenulla 2004–2005 facilisis at reportvero eros et accumsanand our etself-assessment nulla facilisis has beenat vero eros et accumsan et consequat.Zolinza® (vorinostat) Duis autem vel eum iriure dolor inCancer [cutaneousDuis T-cellautem lymphoma vel eum (CTCL)] iriure dolor in expectations for multinational enterprises to create more social value, moving beyond published in December 2005. We have checked by the GRI. Go to the hendrerit in vulputate velit esse molestie iusto odio dignissim qui blandit praesent iusto odio dignissim qui blandit praesent society with superiorhendrerit products in vulputate and velit esse molestie iusto odio dignissim qui blandit praesent iusto odio dignissim qui blandit praesent RESPIRATORY, BONE, ARTHRITIS & ANALGESIA hendrerit in vulputate velit esse molestie hendrerit in vulputate velit esse molestie consequat,compliance vel illum dolore with eu regulations, feugiat luptatum philanthropy zzril delenit augue and duisnormal dolore economicluptatum zzril activities. delenit augue Corporate duis dolore serv ices by developingconsequat, innovations vel illum dolore and eu soughtfeugiat to provideluptatum a comprehensive zzril delenit augueview duisback dolore cover forluptatum more information. zzril delenit augue duis dolore Duis autem vel eum iriure dolor in consequat, vel illum dolore eu feugiat consequat, vel illum dolore eu feugiat of how Merck works, balanced by
Load more

Recommended publications
  • European Life Science Ceo Forum
    WELCOME SPONSORS SPEAKERS PRESENTING COMPANIES 3rd Annual EUROPEAN LIFE SCIENCE CEO FORUM for PARTNERING & INVESTING AWARDS ORGANISATIONS PARTNERING 11-12 February 2010 ConventionPoint, Zurich, Switzerland Conference Guide REGIONAL PARTNERS ORGANISERS EUROPEAN LIFE SCIENCE CEO FORUM www.sachsforum.com WELCOME SPONSORS next Welcome Sachs Associates are delighted to welcome you to the: SPEAKERS PRESENTING COMPANIES 3rd Annual European Life Science CEO Forum for Partnering & Investing 11-12 February 2010 ConventionPoint, Zurich, Switzerland Sachs Associates are delighted to welcome you to the 3rd Annual European Life Science CEO Forum for Partnering & Investing. Following its success from previous years, the forum once again provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas. This exclusive and transactional event complements our Annual Biotech in Europe Investor Forum, held later in the year, but with added focus on Partnering & the pharmaceutical industry, feature presentations from Big Pharma representatives demonstrating their AWARDS ORGANISATIONS PARTNERING current and future partnering strategies through thought-provoking case studies. This year’s programme features a series of panels and presentations from leading investment, pharmaceutical and biotech companies, highlighting the current issues surrounding the evolving M&A market, Vaccines, Medtech Investment and includes special keynote speeches, providing an expert outlook on Europe’s Biotech industry. In addition, the event holds more than 50 company presentations from an exciting and diverse range of publicly listed and private life science companies, looking to raise fi nance and/or fi nd partners. This year’s DyoDelta Life Science Innovation Awards takes place in the evening of the 11th February and the awards recognise exceptional performance in key categories of partnering and fi nancing within the industry.
    [Show full text]
  • 9780813810461.Pdf
    Nursing Care of the Hospitalized Older Patient Nursing Care of the Hospitalized Older Patient Edited by Terry Mahan Buttaro and Kate A. Barba A John Wiley & Sons, Inc., Publication This edition first published 2013 © 2013 by John Wiley & Sons, Inc Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley’s global Scientific, Technical and Medical business with Blackwell Publishing. Editorial Offices 2121 State Avenue, Ames, Iowa 50014-8300, USA The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK 9600 Garsington Road, Oxford, OX4 2DQ, UK For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Blackwell Publishing, provided that the base fee is paid directly to the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923. For those organizations that have been granted a photocopy license by CCC, a separate system of payments has been arranged. The fee codes for users of the Transactional Reporting Service are ISBN-13: 978-0-8138-1046-1/2013. Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book.
    [Show full text]
  • Pharmacology for the Health Care Professions
    Pharmacology for the Health Care Professions Christine M. Thorp University of Salford, UK A John Wiley & Sons, Ltd., Publication Pharmacology for the Health Care Professions Pharmacology for the Health Care Professions Christine M. Thorp University of Salford, UK A John Wiley & Sons, Ltd., Publication This edition first published 2008 2008 by John Wiley & Sons, Ltd. Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley’s global Scientific, Technical and Medical business with Blackwell Publishing. Registered office: John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK Other Editorial Offices: 9600 Garsington Road, Oxford, OX4 2DQ, UK 111 River Street, Hoboken, NJ 07030-5774, USA For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher. Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books. Designations used by companies to distinguish their products are often claimed as trademarks.
    [Show full text]
  • Merck 2012 Corporate Respon
    CORPORATE RESPONSIBILITY REPORT 2011 CORPORATE RESPONSIBILITY CORPORATE RESPONSIBILITY At Merck, corporate responsibility is our daily commitment to discovering innovative solutions to the world’s biggest health challenges. It is this simple promise that informs all of our actions as we apply our global resources, our talents and our scientific and operational expertise to some of the most significant health, environmental and economic challenges in the world today. We see corporate responsibility as a major business objective, not solely a philanthropic initiative. Ultimately, it helps us to discover better ways to deliver greater value to both shareholders and society. Through innovative research, groundbreaking partnerships and smarter processes, we are focusing on four priority areas: Access to Health, Environmental Sustainability, Employees, and Ethics & Transparency. With a focus on these priority areas across our entire organization, we are committed to leading the future of healthcare. 2011 MERCK CORPORATE RESPONSIBILITY REPORT 2 CORPORATE RESPONSIBILITY CEO LETTER Merck is leading the way to a healthier future with products of eliminating river blindness, that touch the lives and improve the well-being of people and a leading cause of preventable communities around the world. Our product portfolio is among blindness, and lymphatic filariasis, the broadest in the healthcare industry. As a leader in global more commonly known as healthcare, we are committed to addressing critical social, elephantiasis. Building on this environmental and economic challenges to ensure not only the legacy of tackling urgent global vitality of our business, but also the health of our world. health challenges such as river blindness, HIV/AIDS and hepatitis, That’s why innovation and corporate responsibility are at the core in September we launched “Merck of our business strategy and activities.
    [Show full text]
  • Ambulatory Patient Safety Toolkit
    2011 Ambulatory Patient Safety Toolkit Property of HealthPartners A resource for clinicians and staff provided by HealthPartners Ambulatory Safety Program Introduction HealthPartners is committed to eliminating harm due to error in the delivery of medical care. The HealthPartners Ambulatory Safety Toolkit provides practical tools and suggestions that you may wish to incorporate into clinical operations or adapt to create your own initiatives. We include links to national and local safety resources and protocols, organized by topic. A complete listing of HealthPartners administrative policies can be found on the Provider Portal at healthpartners.com/portal/p178.html. To date, relatively little research has focused on patient safety in the ambulatory setting. Yet most care is delivered in these settings. Although the ambulatory setting might seem less intense (and less “dangerous”) than an inpatient setting, lapses in safety can and do occur, with adverse consequences. A “culture of patient safety” is an essential ingredient of the safe health care organization. “Culture” can be understood as habits, attitudes, and beliefs that live in the minds of the people who work in the organization and guide the work that they do. Concepts closely related to “culture” are “environment” and “mindset.” The knowledge, skill and judgment of the clinician are essential, of course. In the modern group practice, clinic, and outpatient center, the clinician operates through organizational systems and processes, which together produce the desired clinical outcome. Research has shown that serious errors occur more often from a failure of process and systems, rather than the action of a single individual. Well-designed systems and processes allow the organization to deliver care with reliability, consistency, and resiliency (the ability to detect and quickly recover from an error, before harm occurs).
    [Show full text]
  • 2008 Corporate Responsibility Report. on Behalf of the Board, I Am Very Pleased to Note THOMAS E
    Advancing the Dialogue Toward a Healthier Future Corporate Responsibility 2008 Report Criteria from Millennium UN Global Global Reporting the Access to Development Compact TABLE OF CONTENTS Page Initiative Indicators Medicines Index* Goals† Principles About Merck and this report Inside front cover Message from the CEO 1 Message from the Board 2 Merck’s Approach to CR Reporting 3 » Materiality assessment process 3 » Stakeholder engagement 3 Economic Contribution to Society 4 EC1, SO1 MDG 4; MDG 6; MDG 8 Target 8E » Supporting our communities 5 Summary of Our Progress and Future Plans 6 Researching New Medicines and Vaccines to Address Unmet Needs 8 MDG 4 » R&D impact and performance 9 » Current research pipeline 10 » Expanding our research capabilities and results 10 » Intensifying our research capabilities into diseases prevalent 12 C1, C3, C4 in the developing world » Clinical research and disclosure of results 12 PR3 Principle 10 » Future goals and priorities 14 » Fostering science education 14 EC8, EC9 MDG 2 Improving Access to Medicines, Vaccines and Health Care 16 EC8, EC9 H » Access strategy and management 16 A1, (A2), A3 » Key considerations for our activities 17 D1, D2, E2, F1, F2, G1, G2 » Improving access in the developing world and 19 B2, B3, E3 MDG 1; MDG 4 emerging markets » Improving access to vaccines and immunization 22 B3, E3 MDG 4; MDG 8 Target 4 in the developing world » Improving access to HIV/AIDS treatment and care 23 B3 MDG 4; MDG 6; in the developing world MDG 8 Target 4 » Improving access in developed countries
    [Show full text]
  • Biologics & Biosimilars
    INVENTING WITH PURPOSE CORPORATE RESPONSIBILITY REPORT (2018/2019) COMPLETE WEBSITE COPY AND DATA NOVEMBER 2019 OUR PURPOSE | Overview Our Purpose Overview We have a legacy of saving and improving We live our core commitment to sustainable impact responsibility for using resources wisely and minimizing lives by creating sustainable impact. by managing our business responsibly, following our our environmental footprint. calling to find solutions for some of the world’s most Our approach to corporate responsibility is about the For more than a century, we have been inventing debilitating diseases, striving to reach those in need health, economic, social and environmental impact medicines and vaccines for many of the world’s most with our medicines and vaccines and helping to build we have on individuals and communities around the challenging diseases and we have built a company with robust, durable health systems worldwide through world. We hold ourselves accountable to our many the talent, tenacity and strength to take on some of the partnership, investment and innovation. stakeholders, including patients, employees, customers biggest threats to human and animal health. Operating responsibly as a business is and shareholders, whose perspectives help to define our Reflecting our commitment to managing environmental, corporate responsibility priorities. social and governance (ESG) issues, we continue to at the very heart of our ability to deliver focus our approach to corporate responsibility in four sustainable impact—driving long-term primary areas that are of greatest relevance to our value for our company and society. business and society. y Access to Health We cultivate innovation and excellence by building a diverse and inclusive global workforce, who are y Employees empowered to succeed, personally and professionally.
    [Show full text]